Form 4: Senti Biosciences Director James J. Collins Granted Stock Options

Senti Biosciences, Inc. Director James J. Collins was granted 21,950 stock options with an exercise price of $2.05, vesting over time.

Summary

• James J. Collins, a Director of Senti Biosciences, Inc. (SNTI), was granted 21,950 stock options.
• The stock options have an exercise price of $2.05 per share.
• The grant date for these options was June 25, 2025.
• The options are set to expire on June 24, 2035.
• 100% of the shares underlying this option will vest upon the earlier of the first anniversary of the grant date (June 25, 2026) or the date of the 2026 Annual Meeting, contingent on Mr. Collins' continued service.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is generally a neutral to slightly positive event as it aligns management/director interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options to Director James J. Collins aligns his financial interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from a key board member.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation of continued service from Director James J. Collins through at least the first anniversary of the grant date or the 2026 Annual Meeting.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and broader corporate sectors, serving as a form of non-cash compensation designed to align the interests of board members with those of shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation mechanism widely used across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to attract and retain talent and align long-term incentives.
• Specific comparisons to other companies' director compensation packages would require detailed analysis of their proxy statements (DEF 14A filings), which are not provided in this Form 4.

Related Party Transactions

• The grant of 21,950 stock options to James J. Collins, a Director of Senti Biosciences, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The grant reinforces the compensation structure for key personnel, potentially aiding in retention and motivation.

Next Steps

• The stock options will vest upon the earlier of June 25, 2026, or the date of the 2026 Annual Meeting, subject to continued service.
• Following vesting, Director Collins will have the right to exercise the options to purchase common stock at the specified exercise price until the expiration date of June 24, 2035.

Key Dates

Keywords

Senti Biosciences, SNTI, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant